emjreviews.com10h
New Strategy Enhances PD-1 Therapy in Treatment-Resistant Cancers
A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
Pharmabiz20h
Chugai obtains Japanese regulatory approval for Tecentriq for additional indication of alveolar soft part sarcoma, an ultra-rare disease
Chugai obtains Japanese regulatory approval for Tecentriq for additional indication of alveolar soft part sarcoma, an ultra-rare disease: Tokyo Friday, February 21, 2025, 10:00 Hr ...
Pharmabiz1d
Merus’ petosemtamab receives US FDA breakthrough therapy designation for 1L PD-L1 positive head and neck squamous cell carcinoma
Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...
The Pharma Letter1d
Chugai wins regulatory approval for Tecentriq for additional indication
Japanese drugmaker Chugai Pharmaceutical today announced gaining regulatory approval from the Ministry of Health, Labor and ...
Targeted Oncology1d
FDA Grants Breakthrough Therapy Status to Petosemtamab/Pembrolizumab in HNSCC
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
Targeted Oncology3d
FDA Fast-Tracks IBI363 in Squamous NSCLC
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
The Pharma Letter2d
Petosemtamab granted 2nd Breakthrough Therapy designation by FDA
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to Dutch clinical-stage drug ...
Cure Today1d
Ficerafusp Alfa Trial Begins for Recurrent/Metastatic Head and Neck Cancer
Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.
BioWorld2d
BA-4415, an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
Researchers from Tianjin University have published data regarding development and preclinical characterization of a new anti-PD-L1/CD40 bispecific antibody (BsAb), BA-4415, designed to activate CD40 ...
Merus’ petosemtamab granted Breakthrough Therapy designation by FDA
Merus (MRUS) announced that the FDA has granted Breakthrough Therapy designation to petosemtamab in combination with pembrolizumab for the ...